華北製藥(600812.SH):收到政府土地收儲基本補償款8693.47萬元
格隆匯11月20日丨華北製藥(600812.SH)公佈,根據公司及華北製藥華勝有限公司(原華北製藥集團海翔醫藥有限責任公司)與石家莊市國土資源局(石家莊市土地儲備中心)分別於2008年和2009年簽署的《土地收回(購)合同》,公司可獲得土地收儲基本補償金9.46億元(已收到8.59億元),2020年11月19日,公司及下屬子公司華北製藥華勝有限公司共收到石家莊市財政集中支付中心撥付的剩餘土地收儲基本補償金8693.47萬元。
根據《企業會計準則》及《企業會計準則解釋第3號》相關規定,公司將本次收到的資金衝減其他應收款-石家莊市國土資源局(石家莊市土地收儲中心)8693.47萬元,不影響公司當期損益。具體會計處理須以會計師審計確認後的結果為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.